Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.40 |
| ▸ | CCND1 | P24385 | 9/20 | 0.40 |
| ▸ | CDK9 | P50750 | 5/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CCND3 | P30281 | 3/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625660 | 0.79 | AURKA (0.40) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL1995080 | 0.78 | CCND1 (0.37) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL4189989 | 0.77 | CCNT1 (0.42) | CDK4CCND1CDK9CCNT1CDK2 | |
| SCHEMBL20676931 | 0.74 | CCND1 (0.42) | CDK4CCND1CDK9CCNT1CDK2 | |
| SCHEMBL1990321 | 0.74 | CDK4 (0.67) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL29988033 | 0.74 | CDK4 (0.67) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL27927200 | 0.74 | NUAK1 (0.40) | CDK4CCND1CDK9CCNT1CDK2 | |
| SCHEMBL6363390 | 0.74 | CTSK (0.48) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL2301318 | 0.73 | CDK4 (0.69) | CDK4CCND1CDK9CCNT1CDK1 | |
| SCHEMBL2299575 | 0.73 | CDK4 (0.69) | CDK4CCND1CDK9CCNT1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | CDK4 1/4885CCND1 5/4885CDK9 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.